Allergy Therapeutics’ Shareholders Vote Down Resolution at AGM – MarketWatch
By Ian Walker
Allergy Therapeutics PLC said the decision looking for to take away sure restrictions on share factors wasnt accredited by shareholders On the annual widespread meeting held on Tuesday.
The biotechnology agency said the decision looking for to disapply pre-emption provisions of s561(1) of the CoAct 2006 As a lot as a specified quantity solely acquired 21% of votes forged.
Part 561 of the act requires An group To current current shareholders The prospect To buy new shares beneath The identical, or extra favorable phrases of any problem of equity.
“The board considers The pliability afforded by these authorities to be in Definitely one of the biggest pursuits of The agency and shareholders and notes that this decision has acquired assist at earlier AGMs,” The agency said.
It added thOn the board will proceed To work together with shareholders on their views.
All completely different decisions put forward On the meeting have been accredited.
Write to Ian Walker at [email protected]